Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial First, patient-level correlation was confirmed using ...
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial) The ...
Bottom Line: Adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with chronic lymphocytic leukemia (CLL) to discontinue daily therapy and potentially ...
Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic ...
Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...
MLR may be a useful marker for assessing activity and progression in chronic lymphocytic leukemia (CLL). Patients with CLL had significantly lower MLR values compared to healthy individuals, with ...
Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results